IMED Biotech Unit

We believe ground-breaking science can transform the lives of patients

~ 1 billion USD

Invested each year in scientific research


People with a passion for science


Post docs globally

~ 500

Publications in scientific journals annually

Leading scientific capabilities

Inspiring the next generation

We believe that in order to continue discovering and developing life-changing medicines, we must also continue to inspire the next generation of ground-breaking scientists.

Vibrant science centres

With four research centres across three continents, we know that vibrant and open science centres are a vital part of sustainable innovation.

Open for innovation

What our partners say


Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.



projects in our pipeline


new molecular entity approval in the last quarter


new molecular entities in our late-stage pipeline

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

C/EBP-Homologous Protein (CHOP) in Vascular Smooth Muscle Cells Regulates Their Proliferation in Aortic Explants and Atherosclerotic Lesions

Published: 8 November 2014.

Area: CVMD

AstraZeneca/MedImmune author: Alex-Xianghua Zhou

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

Published: 12 January 2015

Area: Oncology

KCC2 activity is critical in limiting the onset and severity of status epilepticus

Published: 2 March 2015

Area: Neuroscience


Searching for a cure for heart failure

Cardiac regeneration: can science help the heart heal itself?

We know the heart has the potential to heal itself, the question is how? By working together towards a shared goal, these scientists think they might have found the answer
Read full story